• Robert D McBane, Victor D Torres Roldan, Alexander S Niven, Rajiv K Pruthi, Pablo Moreno Franco, Jane A Linderbaum, Ana I Casanegra, Lance J Oyen, Damon E Houghton, Ariela L Marshall, Narith N Ou, Jason L Siegel, Waldemar E Wysokinski, Leslie J Padrnos, Candido E Rivera, Gayle L Flo, Fadi E Shamoun, Scott M Silvers, Tarek Nayfeh, Meritxell Urtecho, Sahrish Shah, Raed Benkhadra, Samer Mohir Saadi, Mohammed Firwana, Tabinda Jawaid, Mustapha Amin, Larry J Prokop, and M Hassan Murad.
• Gonda Vascular Center, Mayo Clinic, Rochester, MN; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
• Mayo Clin. Proc. 2020 Nov 1; 95 (11): 2467-2486.

AbstractA higher risk of thrombosis has been described as a prominent feature of coronavirus disease 2019 (COVID-19). This systematic review synthesizes current data on thrombosis risk, prognostic implications, and anticoagulation effects in COVID-19. We included 37 studies from 4070 unique citations. Meta-analysis was performed when feasible. Coagulopathy and thrombotic events were frequent among patients with COVID-19 and further increased in those with more severe forms of the disease. We also present guidance on the prevention and management of thrombosis from a multidisciplinary panel of specialists from Mayo Clinic. The current certainty of evidence is generally very low and continues to evolve.Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…